Letters

;

Patient groups letter urging the Biden administration to oppose extending the TRIPS waiver

Dec 2, 2022

On behalf of patients battling illnesses such as cancer, HIV, diabetes, genetic disorders, and antibiotic-resistant infections, we write to convey our profound opposition to recent actions supported by the Biden administration regarding intellectual property (IP) protections and express our concerns with potential actions that may further erode IP protections that are necessary to produce lifesaving medicines.

read more

Patient Groups letter on updating SAMHSA HIV block grant criteria for states

Nov 15, 2022

The undersigned 39 organizations of the AIDS Budget and Appropriations Coalition (ABAC), a workgroup of the Federal AIDS Policy Partnership (FAPP), write to request inclusion of critical language in the final FY2023 Labor, HHS Appropriations bill that is necessary to expand our efforts to end the HIV epidemic in the U.S. As you work to finalize the bill, while ABAC continues to advocate for our coalition’s FY2023 funding requests, we urge you to include language that would modernize the way in which states qualify to be eligible for the HIV set-aside of the Substance Abuse Block Grant (SABG).

read more

HIV/AIDS groups letter in support of MassHealth making injectable long-acting PrEP available without barriers

Aug 29, 2022

HIV/AIDS groups are concerned that MassHealth (Massachusetts Medicaid) has not yet added cabotegravir, a new long-acting injectable form of pre-exposure prophylaxis (PrEP) to prevent HIV, to its formulary. We urge MassHealth to make sure injectable long-acting cabotegravir as PrEP is available on formulary without any barriers to access, such as utilization management or prior authorization requirements.

read more

64 organizations request expedited Medicare National Coverage Determination for long-acting injectable PrEP

Aug 5, 2022

We are pleased that the Centers for Medicare and Medicaid Services (CMS) has accepted a request for a National Coverage Determination (NCD) for cabotegravir, a new long-acting injectable form of pre-exposure prophylaxis (PrEP) to prevent HIV.  A National Coverage Determination is the only pathway to coverage under Medicare Part B for a provider-administered drug.  We have, however, been disappointed to learn that CMS has given no timeline for action on this National Coverage Determination, which will make this new long-acting PrEP medication out of reach for potential PrEP users.  Combined with a USPSTF recommendation, an NCD will also make the drug available to Medicare Part B beneficiaries without cost-sharing, thus eliminating one of the biggest barriers to PrEP uptake.

read more

Support for New York’s S.5299-A/A.1741-A on copay assistance

Jul 18, 2022

The HIV+Hepatitis Policy Institute is a leading HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We strongly support S.5299-A/A.1741-A, which would require health insurers to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums. We urge you to sign this legislation into law as soon as possible.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest